<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334057</url>
  </required_header>
  <id_info>
    <org_study_id>NN7088-4484</org_study_id>
    <secondary_id>U1111-1216-4626</secondary_id>
    <nct_id>NCT04334057</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®</brief_title>
  <official_title>Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®. A Multi-centre, Prospective, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Esperoct® in Haemophilia A Patients Under Routine Clinical Practice Conditions in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of Esperoct® for
      long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as
      prescribed by their doctor. The study will last for about 2 years for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse reactions (ARs) reported during the observation period</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs) reported during the observation period</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse reactions (SARs) reported during the observation period</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have confirmed inhibitory antibodies against FVIII during the observation period</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes requiring treatment for patients using Esperoct® during the observation period assessed by annual bleeding rate (ABR)</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the haemostatic response of Esperoct® measured as number of successes for treatment requiring bleeds</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count, assessed based on a four-point scale (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the haemostatic response of Esperoct® measured as number of successes in treatment of bleeds in perioperative management during surgical procedures</measure>
    <time_frame>From baseline (week 0) to end of study (week 104)</time_frame>
    <description>Count, assessed as success/failure based on a four-point scale for haemostatic response (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Patients with haemophilia A</arm_group_label>
    <description>New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turoctocog alfa pegol</intervention_name>
    <description>Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.</description>
    <arm_group_label>Patients with haemophilia A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilia A patients in routine clinical practice in Japan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent obtained before any study-related activities (study-related activities
             are any procedure related to recording of data according to the protocol).

          -  The decision to initiate treatment with commercially available Esperoct® has been made
             by the patient/Legally Acceptable Representative (LAR) and the treating physician
             before and independently from the decision to include the patient in this study.

          -  Diagnosis of haemophilia A in males or females, no age limitation.

          -  New patients who have not previously been exposed to Esperoct®.

        Exclusion Criteria:

          -  Previous participation in this study. Participation is defined as having given
             informed consent in this study.

          -  Known or suspected hypersensitivity to study product or related products.

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor &amp; Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

